These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 37883001)

  • 1. Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.
    Otoda T; Sekine A; Uemoto R; Tsuji S; Hara T; Tamaki M; Yuasa T; Tamaki T; Matsuhisa M; Aihara KI
    Diabetes Ther; 2024 Jan; 15(1):127-143. PubMed ID: 37883001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2i relieve proteinuria in diabetic nephropathy patients potentially by inhibiting renal oxidative stress rather than through AGEs pathway.
    Zeng XC; Tian Y; Liang XM; Wu XB; Yao CM; Chen XM
    Diabetol Metab Syndr; 2024 Feb; 16(1):46. PubMed ID: 38365853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-Sectional and Longitudinal Associations between Skin Autofluorescence and Tubular Injury Defined by Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in People with Type 2 Diabetes.
    Yamagami H; Hara T; Yasui S; Hosoki M; Hori T; Kaneko Y; Mitsui Y; Kurahashi K; Harada T; Yoshida S; Nakamura S; Otoda T; Yuasa T; Kuroda A; Endo I; Matsuhisa M; Abe M; Aihara KI
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma heparin cofactor II activity is inversely associated with albuminuria and its annual deterioration in patients with diabetes.
    Hara T; Uemoto R; Sekine A; Mitsui Y; Masuda S; Kurahashi K; Yoshida S; Otoda T; Yuasa T; Kuroda A; Ikeda Y; Endo I; Honda S; Yoshimoto K; Kondo A; Tamaki T; Matsumoto T; Matsuhisa M; Abe M; Aihara KI
    J Diabetes Investig; 2021 Dec; 12(12):2172-2182. PubMed ID: 34043882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.
    Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sanchez FJ; Gómez Huelgas R; Mateos Polo L; Varela Aguilar JM; Suárez Tembra JM; Arévalo-Lorido JC;
    Int J Clin Pract; 2020 Oct; 74(10):e13586. PubMed ID: 32533906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial.
    Satirapoj B; Korkiatpitak P; Supasyndh O
    Clin Kidney J; 2019 Jun; 12(3):326-332. PubMed ID: 31198224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study.
    Mora-Fernández C; Sánchez-Niño MD; Donate-Correa J; Martín-Núñez E; Pérez-Delgado N; Valiño-Rivas L; Fernández-Fernández B; Ortiz A; Navarro-González JF
    Biomed Pharmacother; 2022 Oct; 154():113677. PubMed ID: 36942605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors attenuate nephrin loss and enhance TGF-β
    Tian Y; Chen XM; Liang XM; Wu XB; Yao CM
    Sci Rep; 2022 Sep; 12(1):15695. PubMed ID: 36127497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure.
    Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL
    Cardiovasc Diabetol; 2022 Sep; 21(1):194. PubMed ID: 36151557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
    Jardine M; Zhou Z; Lambers Heerspink HJ; Hockham C; Li Q; Agarwal R; Bakris GL; Cannon CP; Charytan DM; Greene T; Levin A; Li JW; Neuen BL; Neal B; Oh R; Oshima M; Pollock C; Wheeler DC; de Zeeuw D; Zhang H; Zinman B; Mahaffey KW; Perkovic V
    Clin J Am Soc Nephrol; 2021 Mar; 16(3):384-395. PubMed ID: 33619120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Baseline Clinical Variables on SGLT2i's Antiproteinuric Effect in Diabetic Kidney Disease.
    Capelli I; Ribichini D; Provenzano M; Vetrano D; Aiello V; Cianciolo G; Vicennati V; Tomassetti A; Moschione G; Berti S; Pagotto U; La Manna G
    Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.
    Caravaca-Fontán F; Stevens K; Padrón M; Huerta A; Montomoli M; Villa J; González F; Vega C; López Mendoza M; Fernández L; Shabaka A; Rodríguez-Moreno A; Martín-Gómez A; Labrador PJ; Molina Andújar A; Prados Soler MC; Martín-Penagos L; Yerovi E; Medina Zahonero L; De La Flor JC; Mon C; Ibernon M; Rodríguez Gómez A; Miquel R; Sierra M; Mascarós V; Luzardo L; Papasotiriou M; Arroyo D; Verdalles Ú; Martínez-Miguel P; Ramírez-Guerrero G; Pampa-Saico S; Moral Berrio E; Canga JLP; Tarragón B; Fraile Gómez P; Regidor D; Relea J; Xipell M; Andrades Gómez C; Navarro M; Álvarez Á; Rivas B; Quintana LF; Gutiérrez E; Pérez-Valdivia MÁ; Odler B; Kronbichler A; Geddes C; Anders HJ; Floege J; Fernández-Juárez G; Praga M
    Nephrol Dial Transplant; 2024 Jan; 39(2):328-340. PubMed ID: 37550217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research Implications.
    Rasaratnam N; Salim A; Blackberry I; Cooper ME; Magliano DJ; van Wijngaarden P; Varadarajan S; Sacre JW; Shaw JE
    Am J Kidney Dis; 2024 Jul; 84(1):8-17.e1. PubMed ID: 38551531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.